Plain-English translation of NCT05072600 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing , a medication that helps your immune system recognize and destroy cancer cells. You would receive it as a maintenance therapy after successfully completing a three-part bladder-saving treatment (surgery, radiation, and chemotherapy combined). The goal is to prevent cancer from coming back in other parts of your body.
After bladder-preserving treatment, about 1 in 3 patients develop cancer that spreads to distant organs. Current options for preventing this haven't worked well or have caused too many side effects. This trial is exploring whether this medication can offer a safer way to reduce that risk.
You likely qualify if…
You likely don't qualify if…
You would receive the medication as an injection every 3 weeks for up to 17 cycles (about 12 months), or until your cancer returns or side effects become too severe. During this time, you'll have regular clinic visits to check for side effects and monitor your health through blood tests and scans. The trial will follow you to see whether the medication helps keep your cancer from coming back.
AI-generated summary from trial data · Jun 27, 2026 · Not medical advice
China